← Leaderboards
Jeffrey D Neighbors
Terpenoid Therapeutics, Inc.
$1,916,396
Attributed
$1,916,396
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $875.7K · FY2007–13$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$1,916,396 · 7
By mechanism
R42$782,917 · 1
R43$482,093 · 3
R03$418,403 · 1
R41$232,983 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignPharmaceutical PreparationsAnalogSeriesBiological FactorsPublic Health RelevanceReportingIn VitroBaseIn VivoMalignant NeoplasmsFeasibility StudiesCessation Of LifeLibrariesLeadXenograft ModelBrainCell LineStilbenesProgramsAdvocateDrug KineticsNational Cancer InstituteBinding (Molecular Function)
Grant awards (10)
Feasibility study of GGDPS inhibition for osteoporosis$163,134
R43 · FY2013 · AG · contact PI
Developing Schweinfurthin Analogs as Glioma Therapies$338,914
R42 · FY2010 · NS · contact PI
Pawhuskins: Potential Treatments for Stimulant Abuse.$220,316
R03 · FY2010 · DA · contact PI
Schweinfurthins: novel treatment for breast cancer$204,000
R43 · FY2010 · CA · contact PI
Developing Schweinfurthin Analogs as Glioma Therapies$112,500
R42 · FY2010 · NS · contact PI
Developing Schweinfurthin Analogs as Glioma Therapies$331,503
R42 · FY2009 · NS · contact PI
Pawhuskins: Potential Treatments for Stimulant Abuse.$198,087
R03 · FY2009 · DA · contact PI
Improving the Distribution of Geranylgeranyl Diphosphate synthase inhibitors.$114,959
R43 · FY2009 · CA · contact PI
Preclinical Development of Geranylgeranyl Disphosphate Synthase Inhibitors as Ant$123,123
R41 · FY2007 · CA · contact PI
Novel Glioblastoma Therapeutics$109,860
R41 · FY2007 · CA · contact PI